$18.16
0.67%
Nasdaq, Jan 02, 10:01 pm CET
ISIN
US5907171046
Symbol
MESO

Mesoblast Limited Sponsored ADR Stock price

$18.16
+1.59 9.60% 1M
+7.30 67.22% 6M
+0.12 0.67% YTD
-2.45 11.89% 1Y
+12.34 212.03% 3Y
+1.14 6.70% 5Y
+5.80 46.93% 10Y
+8.66 91.16% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+0.12 0.67%
ISIN
US5907171046
Symbol
MESO
Industry

Key metrics

Basic
Market capitalization
$2.3b
Enterprise Value
$2.3b
Net debt
positive
Cash
$161.2m
Shares outstanding
1.3b
Valuation (TTM | estimate)
P/E
negative | negative
P/S
135.8 | 20.1
EV/Sales
133.8 | 19.8
EV/FCF
negative
P/B
3.9
Financial Health
Equity Ratio
76.1%
Return on Equity
-17.1%
ROCE
-12.1%
ROIC
-14.1%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$17.2m | $116.4m
EBITDA
- | $-1.5m
EBIT
$-82.3m | $-8.3m
Net Income
$-102.1m | $-68.3m
Free Cash Flow
$-50.6m
Growth (TTM | estimate)
Revenue
191.5% | 576.5%
EBITDA
- | 98.2%
EBIT
-23.0% | 89.9%
Net Income
-16.1% | 33.1%
Free Cash Flow
-3.9%
Margin (TTM | estimate)
Gross
70.2%
EBITDA
- | -1.3%
EBIT
-478.5%
Net
-593.9% | -58.7%
Free Cash Flow
-294.4%
More
EPS
$-0.1
FCF per Share
$0.0
Short interest
2.6%
Employees
73
Rev per Employee
$240.0k
Show more

Is Mesoblast Limited Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Mesoblast Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:

Buy
90%
Hold
10%

Financial data from Mesoblast Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
17 17
192% 192%
100%
- Direct Costs 5.13 5.13
67% 67%
30%
12 12
223% 223%
70%
- Selling and Administrative Expenses 39 39
66% 66%
229%
- Research and Development Expense 35 35
37% 37%
202%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -82 -82
23% 23%
-478%
Net Profit -102 -102
16% 16%
-594%

In millions USD.

Don't miss a Thing! We will send you all news about Mesoblast Limited Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mesoblast Limited Sponsored ADR Stock News

Neutral
GlobeNewsWire
3 days ago
NEW YORK, Jan. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that as foreshadowed at the recent Annual General Meeting the Board will undertake a number of changes in line with the Company's evolution to a revenue-generating commercial company.
Neutral
GlobeNewsWire
6 days ago
Mesoblast has option to draw down up to US$125 million by June 30, 2026 New facility does not encumber any of Mesoblast's material assets or intellectual property NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has repaid in full its existing senior secured loa...
Neutral
GlobeNewsWire
24 days ago
NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that an independent peer-reviewed comparative analysis of efficacy and safety between remestemcel-L and ruxolitinib for treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) was presented at the 67th ...
More Mesoblast Limited Sponsored ADR News

Company Profile

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Silviu Itescu
Employees 73
Founded 2004
Website www.mesoblast.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today